Post-Progression Treatments after Palbociclib plus Endocrine Therapy in HR+/HER2– Metastatic Breast Cancer Patients: What Is the Better Choice?
| Autor: | Alessandra Fabi, Mariangela Ciccarese, Sinome Scagnoli, Michelangelo Russillo, Francesco Schettini, Giuseppe Buono, Vito Lorusso, Katia Cannita, Grazia Arpino, Simonetta Stani, Michela Palleschi, Rosalba Rossello, Giuseppina Sarobba, Agnese Fabbri, Marianna Giampaglia, Patrizia Pellegrini, Vincenzo Adamo, Francesca Morelli, Vittoria Barberi, Gianluigi Ferretti, Giovanna Catania, Simona Pisegna, Francesco Cognetti, Diana Giannarelli |
|---|---|
| Přispěvatelé: | Fabi, Alessandra, Ciccarese, Mariangela, Scagnoli, Sinome, Russillo, Michelangelo, Schettini, Francesco, Buono, Giuseppe, Lorusso, Vito, Cannita, Katia, Arpino, Grazia, Stani, Simonetta, Palleschi, Michela, Rossello, Rosalba, Sarobba, Giuseppina, Fabbri, Agnese, Giampaglia, Marianna, Pellegrini, Patrizia, Adamo, Vincenzo, Morelli, Francesca, Barberi, Vittoria, Ferretti, Gianluigi, Catania, Giovanna, Pisegna, Simona, Cognetti, Francesco, Giannarelli, Diana |
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Oncology. |
| ISSN: | 1423-0232 0030-2414 |
| DOI: | 10.1159/000521252 |
| Popis: | Background: To date, a consensus has not yet been reached about the therapy sequence after disease progression (PD) on CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer (MBC). Objectives: The present study assesses, in a real-world setting, the activity of different subsequent therapies in patients who experienced a PD on palbociclib (P) + endocrine therapy (ET), to evaluate the best therapy sequence. Methods: This is a multicenter retrospective observational study. Records of consecutive HR+/HER2- MBC patients from January 2017 to May 2019 were reviewed. The primary endpoint was the evaluation of progression-free survival (PFS) according to subsequent treatment lines after progression on P+ET. Toxicity data were also collected. Results: The outcomes were analyzed in 89 MBC patients that had progressed on previous P+ET: 17 patients were on hormone therapy (HT) and 31 patients on chemotherapy (CT) as second-line treatments; seven patients were on HT and 34 on CT as third-line therapies. PFS of patients treated with HT as second-line therapy is significantly improved when compared with patients treated with CT (p=0.01). Considering third-line settings, the difference in PFS was not statistically different between HT and CT. A better outcome in terms of toxicity is observed among HT patients for both second- and third-line therapies. Conclusions: patients who were progressive on P+ET could still benefit from a subsequent ET. In patients who experienced a good efficacy from prior ET, without visceral metastatic sites, HT seems the most suitable option, when compared to CT, also in terms of safety. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|